🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Eligible patients had high-risk nodal disease or other high-risk features, such as in-transit mets, cPNI, T4 disease, or a high-risk recurrence. After resection patients received at least 50 Gy, but RT details are poorly specified. Then +/- cemiplimab for 48 weeks. Huge win for

Immunotherapy changing the landscape in real time. Amazing progress in high risk skin cancer. #CSCC 🙌🏼 Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma | New England Journal of Medicine nejm.org/doi/full/10.10…

Prof Shankar Siva never fails to impress! Well done on your ✨dazzling✨ presentation at #ASCO25, Shankar Siva . 🤩 “Turning up the sparkle: fresh radiation strategies for #lungcancer” ASCO Peter Mac Cancer Centre Peter Mac Research RANZCR TROG Cancer Research Targeting Cancer Thoracic Oncology Group of Australasia

Our #SABRCAN25 Oligometastasis Speaker! Friday June 6 2025 Shankar Siva Peter Mac Cancer Centre - Oligometastases to and from the Lung: Entry Points to Escape Routes

Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial | JCO Oncology Advances ascopubs.org/doi/10.1200/OA…

Congrats to the colleagues Peter Mac Radiation Oncology Peter Mac Cancer Centre 🇦🇺🇮🇪Shankar Siva Gerry Hanna ! Fred Hutch Cancer Center University of Washington Radiation Oncology UTSW Radiation Oncology Radiation Oncology Bala Vellay

Prof Shankar Siva has received a $1.5M MRFF grant to lead PRIME-Lung — a trial testing if radiotherapy to the primary tumour can boost outcomes in advanced lung cancer (NSCLC). 🔗 Read more: petermac.org/about-us/news-…

Outstanding news!! A win for patients with lung cancer. Huge congratulations to Prof Shankar Siva and team. 👏👏👏 #MRFF #RT #lungcancer #NSCLC Shankar Siva Peter Mac Research Peter Mac Cancer Centre Targeting Cancer RANZCR Thoracic Oncology Group of Australasia TROG Cancer Research University of Melbourne

Awesome! Way to go Shankar Siva and team!

Love this paper! Brilliant collaboration of clinicians, epidemiologists & health services researchers. Geospatial analyses expose diagnostic disparity in #CTCL across 🇦🇺 Open access ➡️doi.org/10.1093/bjd/lj… 🙏 to truly outstanding co-authors, Melbourne Academic Centre for Health & BJD

Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previous studies with goal to continue same systemic treatment #bcsm

Prof. Shankar Siva reminds us that SAFRON II was a “SABR in lieu of systemic therapy” study for patients with lung metastases. #SABRCAN25

If you’re curious what Shankar Siva is up to next, say hello to the recently funded phase III randomized PRIME-LUNG study (n=420). #SABRCAN25

Here is some background justifying the promise of the experimental arm treating the primary tumor “upfront”.

ICYMI: Catch up on all the TOGA action! 💲 Grant success! We're thrilled to celebrate Prof Shankar Siva's achievement in securing a $1.5M grant for PRIME-Lung > buff.ly/fLwbH37

Melissa Barber Shankar Siva I can’t wait to get Back to The Mac this fall.

Congrats to Prof Shankar Siva and the PRIME-Lung research team on receiving this MRFF grant. We're thrilled to be sponsoring this innovative trial aimed at improving outcomes in advanced #lungcancer.

Fantastic to see findings from the C-POST trial that could prove game-changing for the many people at high risk of recurrence of cutaneous squamous cell carcinoma published in NEJM. Congrats to Prof Danny Rischin Peter Mac Cancer Centre & the research team. hubs.ly/Q03rBgRR0